Repligen to Report Fourth Quarter and Full Year 2021 Financial Results
03 févr. 2022 09h30 HE
|
Repligen Corporation
WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2021 financial results on Thursday,...
Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference
30 déc. 2021 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present...
Repligen Corporation to Present at Upcoming Investor Conferences
12 nov. 2021 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at...
Repligen Releases Inaugural Sustainability Report
05 nov. 2021 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today released its inaugural sustainability report, available on the Company’s website. Repligen’s 2020...
Repligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
28 oct. 2021 07h30 HE
|
Repligen Corporation
Reports record revenue of $178.2 million for the quarter, representing year-over-year growth of 89% and organic growth of 77%Raises revenue guidance to $655-$665 million for full year 2021Completes...
Repligen to Report Third Quarter 2021 Financial Results
14 oct. 2021 07h30 HE
|
Repligen Corporation
Webcast and Conference Call to Be Held Thursday, October 28, 2021 at 8:30 a.m. EDT WALTHAM, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the...
Repligen Announces Agreement to Acquire Avitide Inc.
16 sept. 2021 07h40 HE
|
Repligen Corporation
Proposed acquisition strengthens Repligen’s Proteins business Adds a market leader in affinity ligand discovery and development and complements established partnership with Navigo GmbH Strategically...
Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies
09 sept. 2021 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”),...
Repligen Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
27 juil. 2021 07h30 HE
|
Repligen Corporation
Reported revenue was $163.0 million for the quarter, representing year-over-year growth of 86% and organic growth of 69%Revenue guidance raised to $625-$645 million for full year 2021Acquisition of...
Repligen to Report Second Quarter 2021 Financial Results
13 juil. 2021 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2021 financial results on Tuesday, July 27, 2021....